Anti-BCMA CAR-T cell therapy (PersonGen Biomedicine)

N/A

Report date: 2025/10/02 20:00:08

Base Information

Drug NameAnti-BCMA CAR-T cell therapy (PersonGen Biomedicine)
Drug Alias NameBCMA-CAR-TBCMA-CART cell therapy
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-BCMA
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesPersongen Biotherapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd
Active IndicationsN/A
Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A
Related LinksN/A